Spruce Biosciences (SPRB) Stock Price, News & Analysis

Company Overview

Spruce Biosciences, Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for patients with endocrine and rare diseases. Headquartered in Redwood City, California, Spruce was established in 2022 as a strategic spin‐out from Sage Therapeutics and holds global rights, including the United States, Canada, Australia, New Zealand and Israel, to its lead investigational candidate.

The company’s flagship asset is zuranolone, an investigational, oral neuroactive steroid designed as a positive allosteric modulator of GABAA receptors. Zuranolone is being evaluated for the treatment of major depressive disorder and postpartum depression. Spruce has completed multiple pivotal Phase 3 trials and regulatory reviews supporting applications for marketing authorization in its licensed territories. In addition to zuranolone, Spruce Biosciences is advancing next‐generation pipeline programs aimed at addressing other central nervous system and endocrine disorders with significant unmet medical needs.

Since its inception, Spruce has entered into strategic collaborations and licensing agreements to accelerate development and commercialization. The company leverages a lean organizational structure and a seasoned team of drug development professionals to efficiently manage clinical operations, regulatory interactions and commercial planning. Spruce’s research and development operations are complemented by partnerships with contract research organizations and clinical sites across North America and Oceania.

Under the leadership of Chief Executive Officer Jack Lief, who has extensive experience in neuroscience and regulatory strategy, Spruce Biosciences aims to build a sustainable portfolio of therapies for patients with serious neuroendocrine and mood disorders. The company’s management team brings together expertise in clinical development, regulatory affairs and commercial execution to advance its mission of transforming patient care in underserved therapeutic areas.

Key Stats

• Today's Range: $0.07 to $0.11
• 50-Day Range: $0.06 to $0.09
• 52-Week Range: $0.06 to $0.61
• Volume: 2.27 million shs
• Average Volume: 698,565 shs
• Market Capitalization: $3.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.75
• Consensus Rating: Hold

Spruce Biosciences Stock Analysis - MarketRank™

Spruce Biosciences scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Spruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Spruce Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Spruce Biosciences are expected to grow in the coming year, from ($1.00) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spruce Biosciences is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spruce Biosciences is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spruce Biosciences has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.12% of the float of Spruce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Spruce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spruce Biosciences has recently increased by 43.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spruce Biosciences does not currently pay a dividend.

Dividend Growth

Spruce Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.12% of the float of Spruce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Spruce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spruce Biosciences has recently increased by 43.30%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Spruce Biosciences is held by insiders.

Percentage Held by Institutions

91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SPRB Stock Analysis - Frequently Asked Questions

How have SPRB shares performed this year?

Spruce Biosciences' stock was trading at $0.42 at the start of the year. Since then, SPRB stock has decreased by 78.7% and is now trading at $0.0894.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) announced its quarterly earnings results on Tuesday, April, 15th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.37. The business had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.50 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 62.10% and a negative net margin of 555.23%.

When did Spruce Biosciences IPO?

Spruce Biosciences (SPRB) raised $75 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Spruce Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 4/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRB
• CIK: 1683553
• Web: www.sprucebiosciences.com
• Phone: 415-655-4168
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Spruce Biosciences: $1.75
• High Price Target: $3.00
• Low Price Target: $0.50
• Potential Upside/Downside: +1,857.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.92 million
• Net Margins: -555.23%
• Pretax Margin: -555.23%
• Return on Equity: -62.10%
• Return on Assets: -47.49%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.36
• Quick Ratio: 5.36

Sales & Book Value

• Annual Sales: $4.91 million
• Price / Sales: 0.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.88 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 42,231,000
• Free Float: 37,544,000
• Market Cap: $3.78 million
• Optionable: Optionable
• Beta: 2.40